EUVIMEDEUVIMED entdecken
Crossref

Discovery of Novel Dual Inhibitors Targeting Mutant IDH1 and NAMPT for the Treatment of Glioma with IDH1Mutation

Fei Wen, Gang Gui, Xiaoyu Wang, Anqi Qin, Tianfang Ma, Hui Chen, Chunzheng Li, Xiaoming Zha iD

Journal of Medicinal Chemistry · 2024

DOI: 10.1021/acs.jmedchem.3c02482 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Fei Wen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Engineering, School of Engineering, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, China. Hauptthemen laut MEDLINE: Nicotinamide Phosphoribosyltransferase, Isocitrate Dehydrogenase, Glioma, Antineoplastic Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Qinglan Project of Jiangsu Province of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The targeting of cancer cell intrinsic metabolism has emerged as a promising strategy for antitumor intervention. In the study, we identified the first-in-class small molecules that effectively inhibit both mutant isocitrate dehydrogenase 1 (mIDH1) and nicotinamide phosphoribosyltransferase (NAMPT), two crucial targets in cancer metabolism, through structure-based drug design. Notably, compound 23h exhibits excellent and balanced inhibitory activities against both mIDH1 (IC50 = 14.93 nM) and NAMPT (IC50 = 12.56 nM), leading to significant suppression of IDH1-mutated glioma cell (U87 MG-IDH1R132H) proliferation. Significantly, compound 23h has the ability to cross the blood-brain barrier (B/P ratio, 0.76) and demonstrates remarkable in vivo antitumor efficacy (20 mg/kg) in the U87 MG-IDH1R132H orthotopic transplantation mouse models without any notable toxicity. This proof-of-concept investigation substantiates the viability of discovering small molecules that concurrently target mIDH1 and NAMPT, providing valuable leads for the treatment of glioma and an efficient approach for the discovery of multitarget antitumor drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nicotinamide PhosphoribosyltransferaseIsocitrate DehydrogenaseGliomaAntineoplastic AgentsCytokinesCell ProliferationAnimalsHumansMiceCell Line, TumorMutationDrug DiscoveryBrain NeoplasmsStructure-Activity RelationshipEnzyme InhibitorsMice, Nude

Substanzen

Nicotinamide PhosphoribosyltransferaseIsocitrate DehydrogenaseIDH1 protein, humannicotinamide phosphoribosyltransferase, humanAntineoplastic AgentsCytokinesEnzyme Inhibitors

Autor:innen und Institutionen

  • Department of Pharmaceutical Engineering, School of Engineering, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, China.

ORCID-Profile: Xiaoming Zha

Förderung

  • Qinglan Project of Jiangsu Province of China
  • National Natural Science Foundation of China

Zitieren

APA

Wen, F., Gui, G., Wang, X., Qin, A., Ma, T., Chen, H., Li, C., & Zha, X. (2024). Discovery of Novel Dual Inhibitors Targeting Mutant IDH1 and NAMPT for the Treatment of Glioma with IDH1Mutation. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c02482

Vancouver

Wen F, Gui G, Wang X, Qin A, Ma T, Chen H, et al. Discovery of Novel Dual Inhibitors Targeting Mutant IDH1 and NAMPT for the Treatment of Glioma with IDH1Mutation. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.3c02482

BibTeX
@article{Wen2024,
  author = {Wen, Fei and Gui, Gang and Wang, Xiaoyu and Qin, Anqi and Ma, Tianfang and Chen, Hui and Li, Chunzheng and Zha, Xiaoming},
  title = {Discovery of Novel Dual Inhibitors Targeting Mutant IDH1 and NAMPT for the Treatment of Glioma with IDH1Mutation},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  doi = {10.1021/acs.jmedchem.3c02482}
}
Kostenlos starten →